FRX Share Price

Open 100.16 Change Price %
High 100.46 1 Day -0.77 -0.77
Low 99.00 1 Week 0.00 0.00
Close 99.00 1 Month 0.00 0.00
Volume 11101530 1 Year 0.00 0.00
52 Week High 171.08
52 Week Low 134.39
FRX Important Levels
Resistance 2 100.35
Resistance 1 99.80
Pivot 99.49
Support 1 98.20
Support 2 97.65
NYSE USA Most Active Stocks
BAC 22.95 1.68%
BAC 22.95 1.68%
BAC 22.95 1.68%
AMD 10.34 8.16%
AMD 10.34 8.16%
AMD 10.34 8.16%
EMC 29.05 0.97%
EMC 29.05 0.97%
EMC 29.05 0.97%
PCS 11.84 -0.92%
More..
NYSE USA Top Gainers Stocks
POM 26.93 26.79%
POM 26.93 26.79%
CVI 24.77 17.17%
MPX 13.45 13.60%
MPX 13.45 13.60%
FGP 6.70 12.98%
FGP 6.70 12.98%
SAB 7.20 12.50%
SAB 7.20 12.50%
SAB 7.20 12.50%
More..
NYSE USA Top Losers Stocks
ENL 15.81 -66.25%
ENL 15.81 -66.25%
ENL 15.81 -66.25%
OIBR 0.17 -43.33%
MHR 0.15 -42.31%
MHR 0.15 -42.31%
MHR 0.15 -42.31%
STP 0.53 -39.77%
STP 0.53 -39.77%
STP 0.53 -39.77%
More..

Forest Laboratories, Inc. (NYSE: FRX)

FRX Technical Analysis 5
As on 30th Jun 2014 FRX Share Price closed @ 99.00 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 68.57 & Strong Buy for SHORT-TERM with Stoploss of 93.67 we also expect STOCK to react on Following IMPORTANT LEVELS.
FRX Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
FRX Other Details
Segment EQ
Market Capital 9041561600.00
Sector Healthcare
Industry Drug Manufacturers - Other
Offical website http://www.frx.com
FRX Address
FRX
909 Third Avenue
New York, NY 10022
United States
Phone: 212-421-7850
FRX Latest News
Interactive Technical Analysis Chart Forest Laboratories, Inc. ( FRX NYSE USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Forest Laboratories, Inc.
FRX Business Profile
Forest Laboratories, Inc. develops, manufactures, and sells branded forms of ethical drug products in the United States and Europe. The company’s products include Linzess for the treatment of irritable bowel syndrome with constipation or chronic idiopathic constipation; Tudorza Pressair, an antimuscarinic agent to treat bronchospasm associated with chronic obstructive pulmonary disease; Viibryd for the treatment of adults with major depressive disorder (MDD); and Daliresp, a phosphodiesterase-4 enzyme inhibitor to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations in patients with severe COPD. Its products also comprise Teflaro for the treatment of adults with skin and skin structure infections; Bystolic to treat hypertension; Namenda and Namenda XR for the treatment of moderate and severe Alzheimer's disease; Savella to treat fibromyalgia; and Colobreathe, a dry powder inhaler for the treatment of chronic lung infections. In addition, the company develops Levomilnacipran, which is under Phase III clinical trials for the treatment of MDD; Cariprazine that is in Phase III clinical trials to treat acute exacerbation of schizophrenia and acute mania associated with bipolar disorder; ceftazidime/avibactam, which is under Phase III clinical trials for intra-abdominal infections and for complicated urinary tract infections; and Cebranopadol (GRT 6005) that has completed Phase II clinical trials for moderate to severe chronic pain conditions. Forest Laboratories, Inc. sells its products directly to physicians, pharmacies, hospitals, managed care, and other healthcare organizations, as well as through independent distributors. It has collaborative licensing option agreement with Trevena for the development of TRV027 for the treatment of acute decompensated heart failure; and collaboration agreement with Ironwood develop and commercialize Linzess. The company was founded in 1956 and is headquartered in New York, New York. As of May 14, 2014, Forest Laboratories Inc. operates as a subsidiary of Actavis plc.